Puma Biotechnology (NASDAQ:PBYI) Announces Quarterly Earnings Results

Puma Biotechnology (NASDAQ:PBYI) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported $0.19 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.15, FiscalAI reports. The business had revenue of $56.50 million during the quarter, compared to analysts’ expectations of $53.00 million. Puma Biotechnology had a net margin of 11.50% and a return on equity of 21.34%.

Here are the key takeaways from Puma Biotechnology’s conference call:

• NERLYNX revenue and demand improved: Q2 net product revenue rose to $53.6 million from $42.0 million in Q1 and $49.2 million a year ago, while U.S. demand increased 8% sequentially and 11% year over year. Management raised full-year 2026 net product revenue guidance to $205–$209 million.
• Puma reported Q2 GAAP net income of $8.2 million, reversing a $3.8 million loss in Q1, and raised full-year net income guidance to $17–$20 million. The company also made its final $11.1 million loan payment and is now debt-free.
• Alisertib development is progressing, with ALISCA-Breast1 enrollment being narrowed to the 40 mg and 50 mg dose groups and ALISCA-Lung1 now enrolling at 70 mg twice daily. Puma expects to start the combination trial ALISCA-Lung02 in Q3 and provide additional trial data in 2027.
• New prescriptions for NERLYNX declined 6% sequentially, and the company expects higher 2026 R&D spending, up 34%–37% year over year, as clinical trials advance. Q3 net income guidance of $2–$2.5 million is substantially below Q2’s result.
• Full-year royalty guidance was reduced to $19–$22 million from $20–$23 million, partly reflecting a possible late-2026 or 2027 reduction in China royalties if generic NERLYNX reaches a specified market-share threshold.

Puma Biotechnology Stock Performance

Shares of PBYI traded up $0.79 during mid-day trading on Friday, hitting $8.91. 683,217 shares of the company’s stock were exchanged, compared to its average volume of 315,645. The company has a market cap of $453.52 million, a price-to-earnings ratio of 17.13 and a beta of 1.22. Puma Biotechnology has a fifty-two week low of $3.05 and a fifty-two week high of $9.40. The stock’s 50-day moving average is $7.80 and its 200-day moving average is $7.18.

Wall Street Analysts Forecast Growth

PBYI has been the subject of a number of research analyst reports. Weiss Ratings cut shares of Puma Biotechnology from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Wall Street Zen cut Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 16th. Finally, TD Cowen raised their price target on Puma Biotechnology from $5.00 to $6.00 and gave the stock a “hold” rating in a research report on Friday. Two research analysts have rated the stock with a Hold rating, Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $6.00.

Insider Transactions at Puma Biotechnology

In other Puma Biotechnology news, Director Allison Dorval sold 11,610 shares of the firm’s stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $7.20, for a total value of $83,592.00. Following the completion of the transaction, the director owned 90,780 shares of the company’s stock, valued at $653,616. This trade represents a 11.34% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Adrian Senderowicz sold 27,000 shares of the business’s stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $7.20, for a total value of $194,400.00. Following the transaction, the director directly owned 27,000 shares of the company’s stock, valued at approximately $194,400. This represents a 50.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 132,028 shares of company stock valued at $1,006,711. 22.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Puma Biotechnology

Several hedge funds have recently made changes to their positions in the company. BNP Paribas Financial Markets increased its position in Puma Biotechnology by 39.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 8,056 shares of the biopharmaceutical company’s stock valued at $43,000 after acquiring an additional 2,290 shares during the period. Cerity Partners LLC acquired a new stake in Puma Biotechnology during the 2nd quarter worth approximately $36,000. Abel Hall LLC acquired a new stake in Puma Biotechnology during the 4th quarter worth approximately $64,000. Ieq Capital LLC purchased a new position in shares of Puma Biotechnology in the 4th quarter valued at approximately $68,000. Finally, Police & Firemen s Retirement System of New Jersey grew its stake in shares of Puma Biotechnology by 88.9% in the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 15,719 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 7,397 shares during the last quarter. Hedge funds and other institutional investors own 61.29% of the company’s stock.

Puma Biotechnology News Summary

Here are the key news stories impacting Puma Biotechnology this week:

• Positive Sentiment: Second-quarter results exceeded expectations. Puma reported earnings of $0.19 per share, above the $0.04 consensus estimate, while revenue reached $56.5 million versus expectations of $53.0 million. Profitability included a 10.69% net margin and 20.30% return on equity. Puma Biotechnology Q2 2026 earnings results
• Positive Sentiment: Full-year 2026 revenue guidance was raised. Puma now expects revenue of $224 million to $231 million, above the approximately $222.5 million analyst consensus. Rising Nerlynx sales and planned milestones for the alisertib program provide additional potential catalysts. PBYI Q2 earnings and raised guidance
• Neutral Sentiment: Management’s outlook was mixed for the next quarter. Third-quarter revenue guidance of $56 million to $59 million is slightly below the $59.4 million consensus estimate, suggesting that near-term growth may be more modest despite the improved full-year outlook. Puma Biotech Q2 earnings and revenue results
• Negative Sentiment: TD Cowen remains cautious. The firm raised its price target from $5 to $6 but maintained a “hold” rating. The revised target still implies roughly 32.7% downside from the referenced $8.91 share price, potentially weighing on investor sentiment after the recent advance. TD Cowen raises Puma Biotechnology price target

About Puma Biotechnology

Puma Biotechnology, Inc is a late?stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small?molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early?stage HER2-positive breast cancer.